GlassScriptPhysician profile
Karan Ravishankar
NPI 1679005797
$1,513.49
in general payments reported to CMS, 2019-2025
25 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $196 · 2023: $334 · 2024: $398 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $149.65 | 2022-2025 | Repatha |
| Sk Life Science, INC. | $144.68 | 2022-2025 | |
| Ceribell, INC. | $144.30 | 2025 | Pocket Eeg Device |
| W. L. Gore & Associates, INC. | $124.60 | 2024 | Gore Cardioform Septal Occluder |
| Neurocrine Biosciences, INC. | $113.56 | 2022-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $91.87 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sumitomo Pharma America, INC. | $89.41 | 2023 | Aptiom |
| Mdd US Operations, LLC | $80.25 | 2023-2025 | Gocovri, Gocovri |
| Acadia Pharmaceuticals INC | $72.72 | 2024-2025 | Nuplazid |
| Ucb, INC. | $48.99 | 2022-2024 | Briviact |
| Lilly USA, LLC | $43.88 | 2023-2024 | Amyvid |
| Ge Healthcare | $43.45 | 2024-2025 | |
| Averitas Pharma INC. | $43.00 | 2023 | Qutenza |
| Celgene Corporation | $42.64 | 2024-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $34.88 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $32.96 | 2023-2025 | Skyclarys, Leqembi |
| Alexion Pharmaceuticals, INC. | $32.66 | 2023-2025 | Ultomiris |
| Pfizer INC. | $29.83 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.58 | 2023-2024 | Gammagard, Hyqvia |
| Avion Pharmaceuticals | $24.63 | 2022 | |
| Impel Pharmaceuticals INC. | $24.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.62 | 2022 | |
| Genzyme Corporation | $19.61 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.56 | 2022 | |
| Neurelis, INC. | $14.04 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Ravishankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.